USA: Recent findings published in The Journal of Allergy and Clinical Immunology highlight the potential for long-term ...
Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...
AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to ...
Also Read: Amgen/AstraZeneca’s Asthma Drug Tezspire Vs. Sanofi/Regeneron’s Blockbuster Dupixent – Analyst Gives His Pick WAYPOINT is a randomized, double-blind trial that evaluated the ...
Hosted on MSN1d
AstraZeneca plans major $3.5bn expansion drive in the USUK-based biopharmaceutical company AstraZeneca has announced a $3.5bn investment to expand its research and manufacturing ...
Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 companies to do so. The major milestone was a testament to CEO Pascal ...
AstraZeneca may have exited the COVID-19 vaccine market, but it is still hoping to protect vulnerable patients with its antibody sipavibart for pre-exposure prophylaxis (PrEP). The drugmaker said ...
AstraZeneca is backing up its considerable investment in antibody-drug conjugates (ADCs) for cancer with the construction of a $1.5 billion new facility in Singapore to manufacture them.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 17,821.63 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback